Ashley Wallace is a Framingham, Massachusetts based female Optometrist who is specialized in Optometry. Active license number of Ashley Wallace is 5551 for Optometry in Massachusetts. Ashley Wallace examine, diagnose, treat, and manage diseases, injuries, and disorders of the visual system, the eye, and associated structures as well as identify related systemic conditions affecting the eye. She completed pre-professional undergraduate education in a college or university and four years of professional education at a college of optometry, leading to the doctor of optometry (O.D.) degree. She is a eye health care professional who is state-licensed to diagnose and treat diseases and disorders of the eye and visual system.
Complete Profile:
Ashley Wallace speciality, credentials, practice address, contact phone number and fax are as below.
Patients can directly walk in or can call on the below given phone number for appointment.
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details are as mentioned below.
NPI Number:
1770217267
NPI Enumeration Date:
12 Jul, 2022
NPI Last Update On:
18 Jul, 2022
Medical Licenses:
Doctors can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Ashley Wallace are as mentioned below.
License Number
Specialization
State
Status
5551
Optometry
Massachusetts
Primary
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
100 Crossing Blvd, Framingham, Massachusetts
Zip:
01702-5555
Phone Number:
--
Fax Number:
--
Patients can reach Ashley Wallace at 100 Crossing Blvd, Framingham, Massachusetts or can call to book an appointment on 888-964-6681. Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 11 March, 2024.